diarrhea from glp 1 Your guide to GLP-1 side effects Battling a bad case of

Braun Group Baxter International Inc

But beyond their medical applications, an intriguing theory has emerged: could these drugs be contributing to a decline in alcohol sales

Robert Little, founding president and CEO of Kanzen Meal USA, said: This isnt just an incremental health update, its a completely different way to innovate with health and taste first"

Curious if a GLP1 medication could help you reach your health goals

#BMS #Cobenfy #Schizophrenia #Neuroscience #Psychiatry #PharmaNews #DrugDevelopment #Opdivo #Camzyos #AlzheimersDisease #Innovation #Healthcare #Biopharma To view or add a comment, sign in Market Watch | Bristol Myers Squibbs Cobenfy Faces Uptake Challenges Amid Strong Q3 Earnings Bristol Myers Squibb ($BMY) reported $12.2B in Q3 revenue, surpassing analyst expectations yet investor attention centered on Cobenfy, the first new schizophrenia drug in 35 years, which posted $43M in sales, slightly below forecasts

[DOI] [PMC free article] [PubMed] [Google Scholar] [6].Naserpour L, Jalise SZ, Khoshandam M, Hosseinzadeh F